Novacea, Inc. Announces Preliminary Findings From Data Analysis of Ascent-2 Phase 3 Trial

SOUTH SAN FRANCISCO, CA--(Marketwire - June 04, 2008) - Novacea, Inc. (NASDAQ: NOVC) announced today preliminary findings from its ASCENT-2 Phase 3 clinical trial, which compared Asentar™ in combination with Taxotere® (docetaxel) chemotherapy to Taxotere alone in patients with androgen-independent prostate cancer (AIPC). The ASCENT-2 trial was terminated by Novacea in November 2007 due to an unexplained imbalance of deaths between the treatment and control arms of the trial.